Table 1 Clinicopathologic characteristics of study cohort.
ILC (N = 1497) | IDC (N = 5902) | P Value | |
|---|---|---|---|
Age at diagnosis (years), mean (SD) | 60.9 (10.4) | 59.1 (11.1) | <0.001 |
Pathologic stage, n (%) | <0.001 | ||
I | 727 (48.6%) | 3744 (63.4%) | |
II | 664 (44.4%) | 1993 (33.8%) | |
III | 106 (7.1%) | 165 (2.8%) | |
Tumor grade, n (%) | <0.001 | ||
1 | 345 (23.1%) | 1534 (26.0%) | |
2 | 1022 (68.3%) | 3137 (53.2%) | |
3 | 130 (8.7%) | 1231 (20.9%) | |
Clinical risk, n (%) | <0.001 | ||
Low | 719 (48.0%) | 3362 (57.0%) | |
High | 778 (52.0%) | 2540 (43.0%) | |
Genomic risk, n (%) | <0.001 | ||
Low | 1085 (72.5%) | 3435 (58.2%) | |
High | 412 (27.5%) | 2467 (41.8%) | |
Surgical therapy, n (%) | <0.001 | ||
Lumpectomy | 803 (53.6%) | 4018 (68.1%) | |
Mastectomy | 694 (46.4%) | 1884 (31.9%) | |
Adjuvant therapy, n (%) | |||
Chemotherapy | 434 (29.5%) | 2164 (37.4%) | <0.001 |
Endocrine therapy | 1375 (93.4%) | 5270 (91.0%) | 0.003 |
Charlson-Deyo Score, n (%) | 0.434 | ||
0 | 1287 (86.0%) | 5052 (85.6%) | |
1 | 177 (11.8%) | 707 (12.0%) | |
2 | 22 (1.5%) | 114 (1.9%) | |
≥3 | 11 (0.73%) | 29 (0.49%) |
